Tukysa (tucatinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has recurrent or metastatic breast cancer
• Patient has human epidermal growth factor receptor 2 (HER2)-positive disease
• Patient has received at least one prior anti-HER2-based regimen in the metastatic setting
• Medication is used in combination with trastuzumab and capecitabine

Approval duration

1 year